Goldman Sachs raised Sartorius Stedim stock target from EUR 208 to EUR 223
Published on 10/08/2026 at 12:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sartorius Stedim (FR0013154002) was trading at EUR 214.20 at Lang & Schwarz on October 8, 2026 at 11:59 a.m. CEST, while Goldman Sachs had raised its target from EUR 208.00 to EUR 223.00 on September 30, 2026. The analyst view gives the stock a concrete valuation reference as the next results date approaches.
Goldman Sachs lifts its target
According to finanzen.ch, Goldman Sachs kept a Buy rating and raised the Sartorius Stedim target from EUR 208.00 to EUR 223.00. The original research note was dated September 30, 2026, and analyst James Quigley said the recovery in bioprocessing was progressing well.
The target is EUR 8.80 above the Lang & Schwarz price, a 3.95 percent premium to EUR 214.20. That comparison matters because the higher target does not remove the near-term valuation risk implied by the stock's 2.15 percent decline versus its EUR 218.90 prior close.
Half-year growth sets the earnings test
According to Investing.com, first-half 2026 sales rose 7.70 percent operationally in constant currencies. Underlying EBITDA increased 3.90 percent to EUR 548.00 million, while the underlying EBITDA margin reached 30.30 percent.
The mix is important for the next report: the same summary said consumables volume exceeded its pandemic peak and equipment returned to slight growth, while tariff effects and delayed advanced therapy projects from two customers weighed on the Americas. Those figures frame the recovery thesis behind the analyst upgrade more clearly than the target alone.
Next results arrive October 22
Investing.com lists October 22, 2026 as Sartorius Stedim's next earnings date. RBC Capital Markets had kept an Outperform rating and a EUR 210.00 target on October 6, 2026, citing the effects of refunded US tariffs, the Mattek acquisition and currency changes, according to finanzen.at.
Sartorius Stedim was trading at EUR 214.20 at Lang & Schwarz on October 8, 2026 at 11:59 a.m. CEST, down 2.15 percent versus the prior close of EUR 218.90. The 52-week range stood at EUR 150.00 to EUR 225.00 on October 6, 2026, placing the price 4.80 percent below that high. The further course of trading is shown by the continuously updated real-time quote of Sartorius Stedim stock.
Sartorius Stedim market snapshot
- Company: Sartorius Stedim Biotech S.A.
- ISIN: FR0013154002
- Ticker: DIM.PA
- Primary exchange: Euronext Paris
- Price Lang & Schwarz (as of October 8, 2026, 11:59 a.m. CEST): EUR 214.20
- Change versus prior close: minus 2.15 percent
- Prior close Lang & Schwarz (October 7, 2026): EUR 218.90
- Market capitalization: EUR 21.7 billion (as of October 6, 2026)
- 52-week range: EUR 150.00-225.00 (as of October 6, 2026)
- Sector / Industry: Healthcare / Healthcare Equipment and Supplies
- Next earnings date: October 22, 2026
